The literature findings suggest that the presence and progression of MASLD may be indicated by reduced levels of the anti-inflammatory adipokine adiponectin, alongside elevated levels of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β. This evidence concerns the gene TNF and metabolic dysfunction-associated steatotic liver disease.